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Abstract: Fragility fractures that occur as a result of osteoporosis are frequently associated 
with chronic pain and decreased quality of life as well as significant morbidity and mortality. 
Fracture reduction, however, is often less than optimal due to poor compliance with medications. 
Studies have demonstrated that risedronate, a heterocyclic nitrogen containing bisphosphonate 
can reduce vertebral, nonvertebral, and hip fracture incidence in postmenopausal women, in 
men, and in subsets of older patients at great risk of falls and fragility. The mechanism, efficacy, 
dosing options, and tolerability of risedronate are reviewed.
Keywords: osteoporosis, fracture
Osteoporosis is defined as a systemic skeletal disorder characterized by weakening 
of bone mineral and tissue and low bone mass. These changes result in compromised 
bone strength, an increase in bone fragility, and an increased risk of fracture. Although 
the disorder most commonly affects postmenopausal women, 20% of people affected 
in the United States are men.
Fractures are commonly classified into two major types: vertebral and nonvertebral 
fractures. Nonvertebral fractures involve the upper extremity, lower extremity 
(including the hip), ribs, and pelvis. In fact, with the exception of fractures of the 
fingers, toes, skull, and face all fractures after the age of fifty are associated with low 
bone mineral density (BMD).1 Vertebral fractures are the most common osteoporotic 
fracture, occurring in approximately 20% of postmenopausal women. However, 
vertebral fractures often go undiagnosed clinically, and they are the earliest and most 
common fragility-related fracture in postmenopausal women. In the IMPACT study, 
between 29.5%–46.5% of vertebral fractures were undiagnosed.2 Vertebral fractures, 
whether recognized clinically or not, carry with them increased morbidity and mortality. 
These fractures lead to kyphosis, difficulty walking because of change in posture, 
abdominal pain, and potentially respiratory insufficiency.3 Lindsay and colleagues 
demonstrated that approximately 20% of postmenopausal women who have a first 
vertebral fracture will experience another vertebral fracture within one year.4 Once 
one vertebral fracture occurs, other fractures are likely to follow soon after; 25% of 
patients with a first vertebral fracture will go on to have another fracture anywhere in the 
skeleton within one year.5 Hip fractures carry with them great mortality; approximately 
20% of patients with hip fracture patients die within one year, and 30%–50% of these 
patients never regain their original functional status which they had before the hip Clinical Interventions in Aging 2009:4 208
Rackoff Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
fracture.6 These statistics will take on even more significance 
with time. By the year 2050, the incidence of hip fractures 
in the world is expected to increase by 240% in women and 
310% in men.7
Excellent treatment is available to reduce the risk of 
fracture in women and men as well as to decrease osteoporosis-
related mortality. The nitrogen-containing bishosphonates 
have come to be the most widely used drugs in the treatment 
of osteoporosis. There are three oral bisphosphonates which 
are US Food and Drug Administration (FDA)-approved: 
alendronate, risedronate, and ibandronate, and two intrave-
nous bisphosphonates: ibandronate and zolendronate. Other 
FDA options for treatment of osteoporosis include raloxifene, 
hormone replacement therapy, calcitonin, and teriparatide.
Management of osteoporosis
Bisphosphonates are highly potent inhibitors of osteoclastic 
bone resorption, with an initial filling in of resorption cavi-
ties, followed by increased mineralization that is a result of 
the reduced bone turnover.
The three FDA approved oral bisphosphonates: 
alendronate,8 risedronate,9 and ibandronate10 have all 
demonstrated significant vertebral fracture risk reduction, 
respectively. In addition, Black and colleagues demonstrated 
vertebral fracture reduction with intravenous zolendronate 
as a once yearly therapy.11 Furthermore, alendronate,8 
risedronate,12 and zolendronate11 have proven significant hip 
fracture reduction. Risedronate9,12 and zoledronate11 also have 
documented nonvertebral fracture data (Table 1).
Pharmacology
Bisphosphonates are stable chemical P-C-P analogs of 
inorganic pyrophosphate, which itself is characterized by a 
P-O-P structure. Stability is conferred by the carbon atom 
replacing the oxygen atom between the two phosphates. This 
renders the molecule resistant to degradation. Bisphosphonates 
have a high binding affinity to hydroxyapatite in bone and 
are therefore taken up preferentially by the skeleton. When 
osteoclasts resorb hydroxyapatite bound to bisphosphonate 
through endocytosis bone resorption is then impaired. There 
are significant differences among the bisphosphonates in the 
way they bind to bone mineral, which may in turn explain 
some differences in potency, speed of onset, and offset action 
and safety.13
Bisphosphonates have two side groups: R1 and R2. 
Modifications to one or more of these side groups can 
reduce the affinity of the drug for bone as well as decrease 
its biochemical potency. R1 substituents such as hydroxyl 
or amino increase absorption to mineral14 while changing R2 
leads to differences in antiresorptive potency.15
Pamidronate and alendronate have free amino groups 
in their side chains. Ibandronate has a highly substituted 
nitrogen side chain. Risedronate and zoledronate have 
nitrogen-containing groups within heterocyclic rings. It 
is the nitrogen-containing group which inhibits farnesyl 
pyrophosphate synthase (FPPS) along the mevalonate 
pathway.16 FPPS generates isoprenoid lipids that are used 
for post-translational changes of small GTP-binding proteins 
needed for regulation osteoclast function.
The order of potency in inhibiting FPP synthase is: 
zoledronate  risedronate  ibandronate  alendronate.13 
Binding affinities of each individual bisphosphonate also 
contribute to their antiresorptive potency. Nancollas and 
colleagues documented that the R2 side chain determines 
this binding function, with the following binding differences: 
zolendronate  alendronate  ibandronate  risedronate.18 
Risedronate is, therefore, a highly potent inhibitor of FPPS, 
but does not bind to mineral as strongly as alendronate or 
zoledronate. Russell and colleagues proposes that this lower 
mineral binding may enable risedronate to have a wider 
distribution within bone.13 These qualities may explain 
some of its unique pharmacologic effects on bone such as 
early vertebral fracture data. Clinical vertebral fractures 
were not planned endpoints in the early bisphosphonate 
trials. However, post-hoc analysis of the risedronate trials 
show a significant effect on vertebral fracture as early as 
six months (not seen with the other oral antiresorptives), 
suggesting an earlier onset to action than other bisphospho-
nates.17 Two observational studies shed more information 
about the differences among the bisphosphonates. In the 
PROTECT study there was an evaluation of women on 
calcitonin, alendronate, and risedronate. Patients treated 
with risedronate had a significantly lower incidence of 
nonvertebral fractures after six and 12 months compared 
with calcitonin and alendronate.19 In the REAL study, another 
observational study, the outcomes of patients on alendronate 
and risedronate were evaluated. After six and 12 months 
patients on risedronate had significantly lower numbers of 
hip fractures compared to patients on alendronate.20
Intestinal absorption of bisphosphonates is between 
0.6%–3% of an orally administered bisphosphonate.21 The 
absorption of all bisphosphonates is decreased in the pres-
ence of food, most likely because they form a complex 
with divalent cations contained in food such as calcium. 
Therefore, bisphosphonates should be taken on an empty 
stomach with a plain glass of tap water (ie, not mineral or Clinical Interventions in Aging 2009:4 209
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well water which may contain such cations). Patients taking 
risedronate are instructed to wait thirty minutes post-dosing 
before they should eat or drink. They are also instructed not 
to lie down for at least thirty minutes to avoid esophageal 
irritation. Approximately 40%–60% of a dose of risedronate 
is concentrated in the skeleton and the remaining is excreted 
unchanged in the urine.
Clinical efficacy of risedronate
Oral risedronate has been used in the treatment of 
postmenopausal osteoporosis for nearly 11 years. It was 
initially only available as a daily oral dosage regimen of 5 mg 
per day. In 2002 a weekly regimen of 35 mg became available. 
In 2007 a twice monthly dosing regimen on two consecutive 
days was approved by the FDA, and finally, in 2008, a 150 mg 
monthly dose of risedronate was approved.
Fracture data:   vertebral
Two seminal studies, VERT-North America and VERT-
multinational have demonstrated that in patients with post 
menopausal osteoporosis risedronate increases BMD and 
reduces vertebral and nonvertebral fractures.9,22 Inclusion 
criteria in these studies included at least two or more radio-
graphically confirmed vertebral fractures (T4–L4) or one 
vertebral fracture and lumbar spine T score of -2.0. In the 
two studies, risedronate increased BMD by 5.4%–5.9% in 
the lumbar spine and by 1.6%–3.1% in the femoral neck.9,22 
In both studies daily oral risedronate was associated with 
a similar vertebral fracture relative risk reduction (0.51 in 
VERT-NA and 0.59 in VERT-MN). In the larger of the 
two trials, VERT-NA, risedronate reduced the incidence 
of vertebral fractures by 65% in just one year, 49% in 
three years, and reduced nonvertebral fractures by 39% in 
three years.
Fracture data: Nonvertebral
Nonvertebral fractures account for the majority of health 
care-related costs in osteoporosis. Wells and colleagues29 
published a review of the clinical efficacy of risedronate in the 
primary and secondary prevention of osteoporotic fractures 
in postmenopausal osteoporosis compared with untreated 
women over a period of at least one year. A total of seven 
randomized controlled trials were included in the review. 
Two were prevention trials and five were secondary preven-
tion/treatment trials. Four of the secondary prevention trials 
could be pooled for analysis and demonstrated a relative risk 
(RR) of 0.80 (95% confidence interval [CI] = 0.72; p = 0.90) 
in risk of nonvertebral fractures. Three of the secondary 
prevention trials were pooled for analysis and demonstrated 
a RR reduction of 0.74 (95% CI = 0.59; p = 0.94). 
Only risedronate and zoledronate have been documented to 
decrease the risk of nonvertebral fractures and hip fractures 
in an intention to treat population from randomized trials of 
at least three years duration.11,12
Fracture data: Hip
As discussed earlier, hip fractures portend significant morbid-
ity and mortality. Up to 50% of hip fracture patients will have 
permanent functional disability30 and hip fracture increases 
the risk of death by 12%–20%.
The HIP trial was the first randomized controlled trial 
with a bisphosphonate with hip fracture incidence as the pri-
mary outcome. McClung and colleagues12 demonstrated that 
risedronate prevented hip fractures in elderly (70–79 years 
of age) with known osteoporosis by BMD: 1.9% fractures 
in risedronate group over two years versus 3.2% in placebo 
(RR 0.6; 95% CI 0.4 to 0.9; p = 0.009). Interestingly, an 
older group (80 years) that was chosen primarily on the 
basis of clinical risk factors for falls and not BMD did not 
demonstrate any significant reduction in hip fracture. This 
highlights that bisphosphonates require low BMD to prevent 
fracture; the drugs cannot prevent falls themselves. Similar 
findings were seen in the Rotterdam study, in which a large 
European cohort was followed for risk factors for hip frac-
tures. The study revealed a 10-fold increase in hip fracture 
between the groups in their late 90’s compared to the group 
in their late 50’s despite similar T scores between the two 
groups. The increase in hip fracture is thought to be caused 
by factors related to aging and not necessarily to decreases 
in BMD.31
Length of treatment
Safety of bisphosphonates in relation to length of treatment 
has received much attention at present. However, there 
are no clear answers. Efficacy with prolonged treatment is 
well-established. Mellstrom and colleagues23 documented 
a continuous increase in lumbar spine and total hip BMD 
after seven years of treatment. For the first five years of the 
study, women received 5 mg/day of risedronate or placebo. 
However, all women who entered a 6–7 year extension study 
received daily risedronate. A total of 164 women (placebo 
group, 81: risedronate group, 83) entered the 6–7 years 
extension study. Incidence of new vertebral fractures during 
the 6–7 years was similar between the two treatment groups 
(3.8%). Vertebral fracture incidence did not change in the 
seven-year risedronate group during the 6–7 years as compared Clinical Interventions in Aging 2009:4 211
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to the 4–5 years; a significant reduction was observed in the 
original placebo group that switched to risedronate during 
the 6–7 years. The incidence of nonvertebral fractures was 
7.4% and 6.0% in the placebo/risedronate and risedronate 
groups in years 6–7, respectively.
Response to drug treatment is obviously well monitored 
in clinical studies in contrast to the general treatment 
population. Siris and colleagues24 collected data from two 
US claims databases during a five year period, totaling 
35,537 women 45 years and older. The women were pre-
scribed either alendronate or risedronate for 24 months. Only 
43% were found to be refill compliant and 20% persisted with 
treatment during the two years. And there was a progressive 
relationship between refill compliance and fracture risk 
reduction. Lombas and colleagues found that 50% of all 
patients don’t take oral bisphosphonates regularly.25
Dosage options
Because risedronate remains active on bone surface for a 
relatively long period, an extended dosing interval is possible. 
In fact, Brown and colleagues demonstrated noninferiority of 
BMD and markers of bone turnover for the weekly dosage of 
risedronate compared to the daily dosage.26 In addition, the 
incidence of morphometric vertebral fractures was similar 
between the two treatment groups at both one and two years. 
Delmas and colleagues demonstrated similar findings with 
risedronate 75 mg each day for two consecutive days per 
month.27
More recently, once monthly 150 mg risedronate was 
compared to 5 mg daily in an international phase III, random-
ized double blind parallel group multicenter study of post 
menopausal osteoporosis, ie, noninferior.28 Only results of 
the first year has been published; the studying is continuing 
for a second year. The primary endpoint of the monthly study 
was a noninferiority comparing the least mean percentage 
change from baseline in lumbar spine BMD in the 150 mg 
monthly and 5 mg daily groups after a period of 12 months. 
The mean percentage change in lumbar spine BMD was 3.5% 
(95% CI 3.15%–3.93%) in the monthly group and a 3.4% 
(95% CI 3.03%–3.82%) in the daily group. The difference 
between the two groups was –0.1% (95% CI –0.51%–0.27%). 
These results indicated that the once monthly regimen was 
noninferior to the daily regimen. There was also no significant 
difference between treatment groups in BMD of sites in the 
proximal femur, and no significant differences in markers of 
bone turnover at 3, 6, and 12 months.
No difference between the two treatment groups was 
observed in the incidence of vertebral fractures as determined 
by morphometric measurement during the first twelve 
months. Both groups tolerated the drugs well. The percentage 
of patients who withdrew from treatment as result of an 
adverse event was 9.5% in the daily group and 8.6% in the 
once monthly group. The incidence of gastrointestinal (GI) 
adverse events was similar in both groups. The symptoms 
of an acute phase reaction was slightly higher in the once 
monthly group (1.4%) than in the daily group (0.2%). Atrial 
fibrillation was reported in 0.5% of the daily group and 0.6% 
of the once monthly group. No one in the study experienced 
osteonecrosis of the jaw (ONJ).
In the intermittent dosing studies described above, the 
incidence of clinical nonvertebral fractures reported as 
adverse events were similar between the treatment groups, 
however there have been no placebo-controlled studies 
addressing the antifracture efficacy of once weekly or once 
monthly dosing regimen.
Fracture data in high risk populations
In 2006, Ringe and colleagues published a one year study in 
which men with osteoporosis were randomized to risedronate 
5 mg daily versus placebo; risedronate was associated with 
a 60% reduction in the incidence of new vertebral fracture 
(p = 0.028).32 There is excellent data demonstrating that 
risedronate can prevent and treat corticosteroid-induced 
osteoporosis. Patients who received moderate-to-high doses 
of corticosteroids and risedronate daily for one year had a 
70% reduction in vertebral fracture compared to placebo.33
Efficacy of risedronate has been studied in several subsets 
of patients at risk for osteoporosis by Sato and colleagues.34 
A cohort of 280 men 65 years and older poststroke were 
followed for 18 months. BMD decreased poststroke 
secondary to immobilization-induced bone resorption and 
vitamin D deficiency secondary to immobilization. Half of 
the patients received risedronate during the 18 month period 
and half received placebo. There were a similar number of 
falls between the two groups. The RR of hip fracture was 
0.19 (95% CI 0.4–0.89). Sato and colleagues also found a 
significant reduction of hip fracture in elderly female stroke 
patients in a 12-month, randomized, double-blind placebo 
trial of risedronate versus placebo. Seven patients sustained 
hip fractures on the hemiplegic side in the placebo group, 
and one hip fracture occurred in the risedronate group 
(p = 0.0360; odds ratio = 7.0).35 These studies document 
efficacy of residronate on stroke patients despite immobility, 
falls, and vitamin D deficiency.
Patients with Alzheimer’s are another large group at 
risk for bone loss and falls. Sato and colleagues studied Clinical Interventions in Aging 2009:4 212
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500 elderly women (mean age 77.7 years) with Alzheimer’s. 
Both the risedronate and placebo groups showed severe 25 
hydroxyvitamin D deficiency (average 9.1 ng/ml) with 
compensatory hyperparathyroidism. There were 24 hip 
fractures in the control group and 5 hip fractures in the rise-
dronate group (RR 0.28, 95% CI 0.13–0.59). Of note is that 
both groups received 1000 IU of ergocalciferol and 1200 mg 
of elemental calcium and were followed for 28 months.36
BMD is also compromised in Parkinson’s disease 
secondary to immobilization-induced bone resorption and 
hypovitamin D with compensatory hyperparathyroidism. 
Sato and colleagues followed 121 patients with Parkinson’s 
for two years. All patients received vitamin D2 1000 IU, 
Nine patients sustained a hip fracture in the placebo group 
and three patients had hip fractures in the risedronate group 
with a RR reduction of 0.33 (95% CI 0.09–1.20).37
Safety
In general, there is a good safety profile for bisphosphonates. 
The most common tolerability issues have been upper gastro-
intestinal symptoms, influenza-like illnesses, and rarely, ONJ 
and uveitis. Atrial fibrillation has been reported both with 
zolendronic acid and alendronate, but not with risedronate 
to date.
Taggart and colleagues pooled nine multicenter, 
randomized placebo controlled studies of risedronate to 
review the frequency of upper GI events with risedronate. 
Sixty percent of patients had a history of GI tract disease, 
38.7% had active GI tract disease, and 20.5% used antise-
cretory drugs during the studies. Sixty-three percent used 
aspirin and/or nonsteroidal anti-inflammatory drugs during 
the studies. Upper GI adverse events were reported by 
29.6% of patients in the placebo arm compared with 29.8% 
in the risedronate arm. In addition, endoscopy performed 
in 349 patients demonstrated no significant difference 
among the two treatment groups.38 Harris and colleagues 
did a study comparing daily and weekly risedronate and 
similar prevalence of gastrointestinal adverse events among 
treatment groups.39
Osteonecrosis of the jaw is defined as the presence of 
nonhealing exposed bone in the maxillofacial region which 
has not healed within eight weeks and in whom there was no 
history of radiation therapy to the area. Only the maxilla and 
mandible appear to be susceptible. Pazianis and colleagues 
performed a literature review to help further clarify the 
connection between bisphosphonate use and risk of ONJ. 
Of the eleven publications reported in the review only 
26 cases of ONJ were reported.40 Etminam and colleagues 
studied a cohort of 87,837 elderly cardiovascular patients 
who were each on an oral bisphosphonate. The adjusted RR 
for ONJ among all bisphosphonate users was 2.87 (95% CI 
1.71–5.05). The adjusted RR for alendronate, etidronate, 
and risedronate were 2.87 (95% CI 1.46–5.67), 2.43 (95% 
CI 1.05–5.62), and 3.34 (95% CI 1.04–10.67). Of interest, 
is that there were no significant differences in RR of ONJ 
among current users (recent drug exposure within 90 days) 
and past users (drug exposure between 91–365 days before 
diagnosis).41 Marx and colleagues in the Journal of Oral and 
Maxillofacial Surgery compared details from 30 consecutive 
cases of ONJ from oral bisphosphonates with 116 cases from 
intravenous bisphosphonates. In both groups, 50% occurred 
spontaneously and 50% resulted from an oral surgical proce-
dure, mostly tooth removals. There was a direct exponential 
relation between the size of the exposed bone and the duration 
of oral bisphosphonate use. Notably, oral bisphosphonate-
induced osteonecrosis was less frequent, less severe, and 
more responsive to treatment than intravenous-induced 
osteonecrosis.42 According to the American Society for 
Bone and Mineral Research Task Force on Bisphosphonate-
Associated ONJ43 and the American Dental Association 
Council on Scientific Affairs,44 actions that may reduce the 
risk of ONJ in patients about to begin or are currently using 
bisphosphonates include maintenance of good oral hygiene 
and regular dental care.
Renal side effects have also been studied, given that 
bisphosphonates are cleared by the kidney. Miller and 
colleagues pooled results from nine clinical trials, revealing 
no significant differences in incidences of renal toxicity 
between daily risedronate and placebo with baseline renal 
function being the same between the two groups. Risedro-
nate was found to have no effect on specific renal function 
or general adverse events across mild, moderate, and severe 
age-related renal dysfunction.43 Case reports of uveitis and 
scleritis have been reported with bisphophonates, mostly 
alendronate. The ocular events occurred rapidly after treat-
ment and resolved upon cessation.44 Finally, viral-like illness 
has been associated with all the bisphosphonates. These 
symptoms are generally self-limiting, lasting up to 2–3 days 
and do not recur with subsequent dosing.45
Conclusions
There are numerous clinical trials demonstrating the efficacy 
of risedronate in reducing the risk of vertebral, nonvertebral, 
and hip fracture in postmenopausal women, men with 
osteoporosis, men and women with steroid-induced 
osteoporosis and in subsets of patients with immobility Clinical Interventions in Aging 2009:4 213
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diseases at high risk for falls. This antifracture efficacy 
persists over time (seven years) and long term treatment with 
risedronate is well tolerated. Dosing frequency influences 
compliance among patients. Risedronate daily, weekly, 
and monthly have similar BMD changes in the spine and 
hip, similar changes in markers of bone turnover, and 
morphometric vertebral fractures. Given the high morbidity 
and mortality that most fragility fractures carry, treatment 
with risedronate in the appropriate osteoporotic patient is 
warranted.
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